Sanofi: Quarterly beat is fine, but longer-term growth prospects remain questionable
Earnings/Sales releases
The Q1 26 results were ahead of the street’s expectations, backed by strong momentum for the lynchpin immunology medicine Dupixent, impressive uptake of new medicines, and...